Fifth Third Bancorp
ATRS

Fifth Third Bancorp’s Antares Pharma, Inc. ATRS Stock Holding History

Fifth Third Bancorp’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,000
Closed -$3K – 2288
2017
Q1 		$3K Hold
1,000
– – ﹤0.01% 1953
2016
Q4 		$2K Hold
1,000
– – ﹤0.01% 2091
2016
Q3 		$2K Buy
+1,000
New +$1.23K ﹤0.01% 2121

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fifth Third Bancorp's ATRS Position: Q2 2017 in Review

Fifth Third Bancorp sold out of Antares Pharma, Inc. (ATRS) in Q2 2017, closing a stake of 1,000 shares — an estimated $3K sold.

Fifth Third Bancorp first reported a position in ATRS in Q3 2016 and held it in 3 quarters. The position peaked at $3K in Q1 2017. 103 funds tracked by Wall St. Rank hold ATRS as of Q2 2017.

  • Fifth Third Bancorp reported no remaining Antares Pharma, Inc. position as of Q2 2017 after selling out during the quarter.
  • Fifth Third Bancorp sold 1,000 Antares Pharma, Inc. shares in Q2 2017, an estimated $3K.
  • Fifth Third Bancorp first reported a position in Antares Pharma, Inc. in Q3 2016 and held it in 3 quarters.
  • Fifth Third Bancorp's Antares Pharma, Inc. position peaked at $3K in Q1 2017.
  • 103 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2017.

Based on Fifth Third Bancorp's 13F filing for Q2 2017, filed 11 Aug 2017.